EKR Therapeutics Report issue

For profit Phase 4
Founded: Bedminster NJ United States (2005)
Status: Acquired by Cornerstone Therapeutics (2012) → now Chiesi (2014)

Organization Overview

First Clinical Trial
2005
NCT00728832
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

EKR | EKR THERAP | EKR Therapeutics, Inc

Active Ingredients

Marketed Drugs (1)

reteplase (Retavase) (1998)

Drugs in Phase 4 Trials (3)

labetalol (trandate) (1 trial)

morphine (4 trials)

nicardipine (cardene) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Emergencies (Phase 4)

Pain, Postoperative (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 3